Efficacy and Safety of 125I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single-Arm Meta-Analysis of Chinese Patients

IF 1.5 Q4 ONCOLOGY

Cancer reports Pub Date : 2024-08-19 DOI:10.1002/cnr2.2147

Yunxin Wang, Yuhong Ma, Lijuan Zou, Hongwei Lei, Yun Teng, Fuxiu Ye, Feng Zhang, Haichen Zhang

{"title":"Efficacy and Safety of 125I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single-Arm Meta-Analysis of Chinese Patients","authors":"Yunxin Wang, Yuhong Ma, Lijuan Zou, Hongwei Lei, Yun Teng, Fuxiu Ye, Feng Zhang, Haichen Zhang","doi":"10.1002/cnr2.2147","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The study aimed to assess the efficacy and safety of <sup>125</sup>I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta-analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression-free survival, overall survival, and adverse events.</p>\n </section>\n \n <section>\n \n <h3> Recent Fidings</h3>\n \n <p>The meta-analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In conclusion, this meta-analysis confirmed that <sup>125</sup>I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>PROSPERO: CRD42023423857</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 8","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.2147","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.2147","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The study aimed to assess the efficacy and safety of ¹²⁵I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta-analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression-free survival, overall survival, and adverse events.

Recent Fidings

The meta-analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.

Conclusion

In conclusion, this meta-analysis confirmed that ¹²⁵I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients.

Trial Registration

PROSPERO: CRD42023423857

Abstract Image

查看原文本刊更多论文

125I粒子植入治疗放疗后盆腔复发性宫颈癌的有效性和安全性：中国患者的单臂Meta分析

研究背景该研究旨在评估 125I 粒子植入治疗放疗后盆腔复发宫颈癌的有效性和安全性。该荟萃分析已在 PROSPERO 上注册。我们在 CNKI、万方数据库、CBM、PubMed、Embase、Cochrane Library 和 Web of Science 等数据库中查找了相关研究。终点指标包括客观反应率、疾病控制率、无进展生存期、总生存期和不良事件：荟萃分析包括六项研究，共有 246 名患者。肿瘤反应的汇总 ORR 为 63%，DCR 为 87%。中位 PFS 为 9.09 个月，中位 OS 为 13.46 个月。≥III级不良反应发生率为6%：总之，该荟萃分析证实，125I粒子植入治疗放疗后盆腔复发宫颈癌具有良好的局部控制率和较高的安全性，可作为放疗后盆腔复发宫颈癌的补救治疗方法，延长患者的生存时间：试验注册：PROCROPERO：CRD42023423857。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊